In Vivo Labeling of Brain Capillary Endothelial Cells after Intravenous Injection of Monoclonal Antibodies Targeting the Transferrin Receptor

The development of vectors for drug delivery to the central nervous system remains a major pharmaceutical challenge. Here, we have characterized the brain distribution of two monoclonal antibodies (MAbs) targeting the mouse transferrin receptor (TfR) (clones Ri7 and 8D3) compared with control IgGs after intravenous injection into mice. MAbs were fluorolabeled with either Alexa Fluor (AF) dyes 647 or 750. Intravenous injection of Ri7 or 8D3 MAb coupled with AF750 led to higher fluorescence emission in brain homogenates compared with control IgGs, indicating retention in the brain. Fluorescence microscopy analysis revealed that AF647-Ri7 signal was confined to brain cerebrovasculature, colocalizing with an antibody against collagen IV, a marker of basal lamina. Confocal microscopy analysis confirmed the delivery of injected Ri7 MAb into brain endothelial cells using the pericyte marker anti-α-smooth muscle actin, the endothelial marker CD31, and the collagen IV antibody. No evidence of colocalization was detected with neurons or astrocytes identified using antibodies specific for neuronal nuclei or glial fibrillary acidic protein, respectively. Our data show that anti-TfR vectors injected intravenously readily accumulate into brain capillary endothelial cells, thus displaying strong drug-targeting potential.

[1]  R. Gabathuler,et al.  Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases , 2010, Neurobiology of Disease.

[2]  S. Cazaubon,et al.  The blood-brain barrier in brain homeostasis and neurological diseases. , 2009, Biochimica et biophysica acta.

[3]  R. Deane,et al.  Clearance of amyloid-β peptide across the blood-brain barrier: Implication for therapies in Alzheimer’s disease , 2009 .

[4]  J. Scherrmann,et al.  CNS Delivery Via Adsorptive Transcytosis , 2008, The AAPS Journal.

[5]  W. Jefferies,et al.  A Unique Carrier for Delivery of Therapeutic Compounds beyond the Blood-Brain Barrier , 2008, PloS one.

[6]  Michel Demeule,et al.  Identification and Design of Peptides as a New Drug Delivery System for the Brain , 2008, Journal of Pharmacology and Experimental Therapeutics.

[7]  B. Zlokovic The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders , 2008, Neuron.

[8]  E. Morgan,et al.  Iron trafficking inside the brain , 2007, Journal of neurochemistry.

[9]  B. Davidson,et al.  Transvascular delivery of small interfering RNA to the central nervous system , 2007, Nature.

[10]  W. Pardridge Drug Targeting to the Brain , 2007, Pharmaceutical Research.

[11]  A. Fagan,et al.  P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. , 2005, The Journal of clinical investigation.

[12]  G. Storm,et al.  Targeting Anti—Transferrin Receptor Antibody (OX26) and OX26-Conjugated Liposomes to Brain Capillary Endothelial Cells Using In Situ Perfusion , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  G. Bu,et al.  Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier , 2004, Journal of Cell Science.

[14]  Sylvain V Costes,et al.  Automatic and quantitative measurement of protein-protein colocalization in live cells. , 2004, Biophysical journal.

[15]  T. Shimazoe,et al.  In vivo delivery of glial cell-derived neurotrophic factor across the blood-brain barrier by gene transfer into brain capillary endothelial cells. , 2003, Human gene therapy.

[16]  Hongzhe Sun,et al.  Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway , 2002, Pharmacological Reviews.

[17]  Michel Demeule,et al.  High transcytosis of melanotransferrin (P97) across the blood–brain barrier , 2002, Journal of neurochemistry.

[18]  Y. Kaneda,et al.  Transluminal Gene Transfer into Brain Capillary Endothelial Cells In Vivo with HVJ-liposomes , 2002, Journal of drug targeting.

[19]  E. Morgan,et al.  Restricted transport of anti‐transferrin receptor antibody (OX26) through the blood–brain barrier in the rat , 2001, Journal of neurochemistry.

[20]  M. J. Coloma,et al.  Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor , 2000, Pharmaceutical Research.

[21]  B. Engelhardt,et al.  Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. , 2000, The Journal of pharmacology and experimental therapeutics.

[22]  B. Engelhardt,et al.  Immunohistochemical localization of the murine transferrin receptor (TfR) on blood–tissue barriers using a novel anti-TfR monoclonal antibody , 1998, Histochemistry and Cell Biology.

[23]  T. Moos Immunohistochemical localization of intraneuronal transferrin receptor immunoreactivity in the adult mouse central nervous system , 1996, The Journal of comparative neurology.

[24]  R. Broadwell,et al.  Transcytosis of Protein through the Mammalian Cerebral Epithelium and Endothelium III. Receptor-Mediated Transcytosis through the Blood–Brain Barrier of Blood-Borne Transferrin and Antibody against the Transferrin Receptor , 1996, Experimental Neurology.

[25]  W. Pardridge,et al.  Transport of [125I]transferrin through the rat blood-brain barrier , 1995, Brain Research.

[26]  T. Moos Age-dependent uptake and retrograde axonal transport of exogenous albumin and transferrin in rat motor neurons , 1995, Brain Research.

[27]  U. Bickel,et al.  In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[28]  W. Pardridge,et al.  Transport of Human Recombinant Brain-Derived Neurotrophic Factor (BDNF) Through the Rat Blood−Brain Barrier in Vivo Using Vector-Mediated Peptide Drug Delivery , 1994, Pharmaceutical Research.

[29]  W. Pardridge,et al.  Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. , 1991, The Journal of pharmacology and experimental therapeutics.

[30]  R. Starzyk,et al.  Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Mash,et al.  Characterization and Distribution of Transferrin Receptors in the Rat Brain , 1990, Journal of neurochemistry.

[32]  B. Giometto,et al.  Transferrin receptors in rat central nervous system An immunocytochemical study , 1990, Journal of the Neurological Sciences.

[33]  W. Pardridge,et al.  Human blood-brain barrier transferrin receptor. , 1987, Metabolism: clinical and experimental.

[34]  W. Jefferies,et al.  Transferrin receptor on endothelium of brain capillaries , 1984, Nature.

[35]  P. Dore‐Duffy,et al.  Morphology and properties of pericytes. , 2011, Methods in molecular biology.

[36]  R. Deane,et al.  Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. , 2009, CNS & neurological disorders drug targets.

[37]  T. Nishizaki,et al.  Transferrin receptors in injured brain , 2004, Acta Neuropathologica.

[38]  W. Pardridge,et al.  Global non-viral gene transfer to the primate brain following intravenous administration. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  F. Calon,et al.  Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. , 2003, Human gene therapy.

[40]  W. Pardridge,et al.  Noninvasive gene targeting to the brain. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[41]  B. Bregman,et al.  Localization of transferrin within the developing vertebrate nervous system. , 1988, Revue neurologique (Paris).